FDA asks Endo to take pain drug off market
By 
Sarah Houlton2017-06-15T12:05:00
Request part of larger strategy to address opioid misuse in the US
The US Food and Drug Administration (FDA) has asked Endo Pharmaceuticals to withdraw its extended relief opioid pain medication, Opana ER (oxymorphone) from the market. But what else is the US doing to tackle painkiller misuse?